|
Accrued
expenses consisted of the following:
SCHEDULE OF ACCRUED EXPENSES
| |
|
2020 |
|
|
2019 |
|
| |
|
December
31, |
|
| |
|
2020 |
|
|
2019 |
|
| Accrued
clinical operations and trials costs |
|
$ |
14,132,842 |
|
|
$ |
14,242,669 |
|
| Accrued
product development costs |
|
|
2,189,047 |
|
|
|
3,573,231 |
|
| Accrued
compensation |
|
|
4,222,594 |
|
|
|
3,673,111 |
|
| Accrued
other |
|
|
1,460,949 |
|
|
|
958,928 |
|
| Total |
|
$ |
22,005,432 |
|
|
$ |
22,447,939 |
|
|